Status:
COMPLETED
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Central Nervous System Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response a...
Detailed Description
PRIMARY OBJECTIVES: I. The primary objective of this pilot study is to assess the efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase i...
Eligibility Criteria
Inclusion
- Patients must have a clinical diagnosis of a primary central nervous system tumor
- Patients must be eligible to receive the influenza vaccine
- Patients must be able to provide written informed consent
Exclusion
- Patients unable to receive the influenza vaccine due to history of allergy to egg proteins, allergy to influenza vaccine component, acute febrile illness at the time of proposed vaccine administration, history of clinically or virologically confirmed influenza infection in the previous 6 months, contraindication to intramuscular injections, Guillan-Barré syndrome, or other contraindication to the vaccine
- Patients who have received the 2011-2012 annual influenza vaccine prior to being considered for enrollment on this study
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01474174
Start Date
September 1 2011
End Date
July 1 2012
Last Update
July 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157